지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2012.1
- 수록면
- 1 - 18 (18page)
이용수
초록· 키워드
오류제보하기
Schizophrenia is a devastating psychiatric illness that afflicts 1% of the population worldwide, resulting in substantial impact to patients, their families, and health care delivery systems. For many years, schizophrenia has been felt to be associated with dysregulated dopaminergic neurotransmission as a key feature of the pathophysiology of the illness. Although numerous studies point to dopaminergic abnormalities in schizophrenia, dopamine dysfunction cannot completely account for all of the symptoms seen in schizophrenia, and dopamine-based treatments are often inadequate and can be associated with serious side effects. More recently, converging lines of evidence have suggested that there are abnormalities of glutamate transmission in schizophrenia. Glutamatergic neurotransmission involves numerous molecules that facilitate glutamate release, receptor activation, glutamate reuptake, and other synaptic activities. Evidence for glutamatergic abnormalities in schizophrenia primarily has implicated the NMDA and AMPA subtypes of the glutamate receptor. The expression of these receptors and other molecules associated with glutamate neurotransmission has been systematically studied in the brain in schizophrenia. These studies have generally revealed region- and molecule-specifi c changes in glutamate receptor transcript and protein expression in this illness. Given that glutamatergic neurotransmission has been implicated in the pathophysiology of schizophrenia, recent drug development efforts have targeted the glutamate system. Much effort to date has focused on modulation of the NMDA receptor, although more recently other glutamate receptors and transporters have been the targets of drug development. These efforts have been promising thus far, and ongoing efforts to develop additional drugs that modulate glutamatergic neurotransmission are underway that may hold the potential for novel classes of more effective treatments for this serious psychiatric illness.
목차
등록된 정보가 없습니다.
참고문헌 (214)
참고문헌 신청
Aanonsen, L. M. / 1986 / Phencyclidine selectively blocks a spinal action of N-methyl-D-aspartate in mice / Neurosci. Lett 67:191~197
Aihara, Y. / 2000 / Molecular cloning of a novel brain-type Na(+)- dependent inorganic phosphate cotransporter / J. Neurochem 74:2622~2625
Akbarian, S. / 1996 / Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics / J. Neurosci 16:19~30
Anggono, V. / 2011 / PICK1 loss of function occludes homeostatic synaptic scaling / J. Neurosci 31:2188~2196
Arai, A. / 1996 / Effects of a memory-enhancing drug on DL-alpha-amino-3-hydroxy-5-methyl- 4-isoxazolepropionic acid receptor currents and synaptic transmission in hippocampus / J. Pharmacol. Exp. Ther 278:627~638
Aihara, Y. / 2000 / Molecular cloning of a novel brain-type Na(+)- dependent inorganic phosphate cotransporter / J. Neurochem 74:2622~2625
Akbarian, S. / 1996 / Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics / J. Neurosci 16:19~30
Anggono, V. / 2011 / PICK1 loss of function occludes homeostatic synaptic scaling / J. Neurosci 31:2188~2196
Arai, A. / 1996 / Effects of a memory-enhancing drug on DL-alpha-amino-3-hydroxy-5-methyl- 4-isoxazolepropionic acid receptor currents and synaptic transmission in hippocampus / J. Pharmacol. Exp. Ther 278:627~638
이 논문의 저자 정보
최근 본 자료
댓글(0)
0